LifeMD: Still Undervalued Despite Earnings Miss

LifeMD reported disappointing Q2 2026 results, cut revenue and EBITDA guidance, and saw subscribers decline sequentially. Its core model retains an 88% gross margin, but customer acquisition costs have risen to 59% of revenue, compressing EBITDA. Management is pivoting from auction-based advertising toward manufacturer, employer and insurer partnerships to lower CAC and expand branded GLP-1 therapy utilization, while the analyst maintains a Buy rating.

Analysis

LFMD is transitioning from a performance-marketing growth model to a channel-development model, which changes both the earnings profile and valuation framework. Near term, partnerships may depress reported growth because enterprise, payer, and manufacturer sales cycles are materially longer than direct-to-consumer acquisition; the market is unlikely to underwrite CAC relief until management discloses signed-partner economics, conversion rates, and contribution margins. The key question is whether lower acquisition spend is genuinely structural or simply reflects reduced demand intensity after the GLP-1 telehealth land-grab.

The potential upside is asymmetric only if branded GLP-1 access improves retention and monetization versus compounded alternatives. Manufacturer and insurer relationships could reduce regulatory and supply-chain risk while raising lifetime value through recurring prescription management, but they also increase counterparty concentration and may shift economics toward lower-margin fulfillment or referral fees. Over the next 1-3 months, another guidance reset or continued sequential subscriber erosion would likely compress the multiple further; over 6-18 months, proof that partnership cohorts acquire at materially lower CAC and retain better than DTC cohorts could justify a rerating.

Consensus appears too willing to extrapolate the stated gross-margin profile into EBITDA recovery. In telehealth, customer acquisition is not merely a discretionary expense when competitors can bid for the same high-intent patients; CAC can reaccelerate quickly if GLP-1 supply expands, branded-drug marketing intensifies, or reimbursement changes make consumers more valuable. The thesis is falsified if CAC falls but revenue per subscriber and retention deteriorate, indicating that reduced spend is sacrificing customer quality rather than improving channel efficiency.

Key Decisions for Investors

• Do not add directional LFMD exposure before the next operating update; treat it as a watch-list long contingent on disclosed evidence that partnership-sourced cohorts have lower CAC and equal-or-better retention than DTC cohorts. A credible inflection should be visible within 1-2 quarters, not merely through announced partnerships.
• For existing longs, reduce gross exposure into the next earnings event unless the position is sized as venture-like optionality. The downside case is another guidance reduction and multiple compression; retain only a small core position if the expected payoff from validated channel economics is at least 3:1 versus a further earnings-driven drawdown.
• Set explicit triggers: add only if customer acquisition expense declines as a share of revenue while subscriber trends stabilize and adjusted EBITDA guidance is maintained or raised; exit if subscriber contraction persists for two quarters, EBITDA losses widen despite lower marketing spend, or a major branded-therapy partner fails to convert into measurable revenue.
• Monitor HIMS, AMWL, and TDOC as competitive read-throughs rather than immediate pair shorts. Evidence that scaled platforms sustain growth while LFMD retrenches would indicate share loss; broad deterioration in GLP-1 telehealth demand would instead make an LFMD-specific long thesis inappropriate.